Treatment of neovascular age related macular degeneration with intravitreal Bevacizumab (Avastin)
- Conditions
- neovascular age-related macular degeneration
- Registration Number
- EUCTR2006-001914-34-DE
- Lead Sponsor
- Bert Mueller, Dep. Ophthalmology
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Patients older than 50 years, neovascular age related macular degeneration, loss of visual acuity within 3 months prior to inclusion
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range
Exclusion Criteria
allergy to bevacizumab, contraindication to bevacizumab (unstable Angina pectoris, recent myocardial infarction and stroke), other ocular disease
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Primary end point(s): primary endpoint: loss of more than 15 letters ;Main Objective: To test effeciacy and safety of 1mg intravitreal Bevacizumab in patients with neovascular age related macular degeneration and recent loss of visual acuity <br>;Secondary Objective: to test reading velocity, contrast sensitivity, visual fixation ability, vascular permeability, quality of life questionaire,
- Secondary Outcome Measures
Name Time Method